Bryan Morton, Chairman
Professor Bryan Morton CBE is Chairman of VHsquared, with over 30 years’ experience as an entrepreneur, Board member and senior manager in the pharmaceutical industry. He brings specific expertise in strategy, business development and private equity/venture capital deals.
Bryan was previously CEO of EUSA Pharma, a global speciality oncology company, which was acquired by Jazz Pharmaceuticals in 2012 for $700 million. After founding EUSA in 2005, Morton was able to fund the company’s growth by raising $265 million from several prominent life science investors, including Goldman Sachs, Essex Woodland, 3i, Advent, SV Life Sciences, Neomed and Novaquest. In 2003, Morton founded and was appointed CEO of Zeneus Pharma Ltd, a European speciality oncology and critical care company. He sold Zeneus to Cephalon for $360 million, delivering generous returns to Apax Partners, an early investor. Prior to running Zeneus, Morton was president of Convatec, EMEA and spent over 20 years in positions of increasing responsibility at Merck & Co (NYSE: MRK).